Comparison of Myeloablative Busulfan/Cyclophosphamide and Busulfan/Fludarabine for Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis
HematologiaSobre o estudo
- Desenho
- Metanálise
- Nível de evidência
- 1 · Evidência consolidada
- Revista
- Transplantation and cellular therapy
- Publicado em
- 3 dez 2025
- Citações
- 1
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Comparison of Myeloablative Busulfan/Cyclophosphamide and Busulfan/Fludarabine for Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis
Tomohito Shimada, Tetsuhiro Masaki, Ryosuke Koyamada, Kazuhiro Ishikawa, Shinya Yamanaka, Kuniko Sato, Erika Ota, Takuya Yamashita, Shinichiro Mori
Descritores MeSH
- Myeloablative Agonists
- Cyclophosphamide
- Hematologic Neoplasms
- Busulfan
- Vidarabine
- Hematopoietic Stem Cell Transplantation
- Transplantation Conditioning
- Humans
- Transplantation, Homologous
Veja também
Estudos relacionados
- Outcomes of fludarabine-melphalan versus fludarabine-busulfan reduced-intensity conditioning regimens for allogeneic hematopoietic stem cell transplantation in patients with hematologic malignancies: A systematic review and meta-analysis
- Busulfan-fludarabine versus busulfan-cyclophosphamide for allogeneic transplant in acute myeloid leukemia: long term analysis of GITMO AML-R2 trial
- Reduced intensity versus myeloablative conditioning for MDS: long-term results of an EBMT phase III study (RICMAC)
- Myeloablative conditioning regimens in adult patients with acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation in complete remission: a systematic review and network meta-analysis